Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows positive revenue growth and a strong cash position, but there are concerns about increased R&D expenses and net losses. The Q&A highlights ongoing trials with some promising interim results, but uncertainties remain about future trial outcomes and competitive pressures. Management's reluctance to provide specific guidance on FYARRO sales adds to the uncertainty. Overall, these factors suggest a neutral stock price movement in the short term.
Key Financial Performance
FYARRO net product sales Q4 2023 $6.3 million, representing 21% growth over Q4 2022.
FYARRO net product sales full year 2023 $24.4 million, an increase of 60% over prior year sales of $15.2 million.
Research and Development expenses Q4 2023 $12.8 million, compared to $9.4 million in Q4 2022.
Research and Development expenses full year 2023 $48.9 million, compared to $32.7 million last year.
Selling, General and Administrative expenses Q4 2023 $10.3 million, compared to $11.1 million in Q4 2022.
Selling, General and Administrative expenses full year 2023 $44.5 million, compared to $40.2 million in the prior year.
Net loss Q4 2023 $16.3 million, compared to $13.9 million in Q4 2022.
Net loss full year 2023 $65.8 million, compared to $60.5 million in the prior year.
Cash, cash equivalents and short-term investments at end of Q4 2023 $108.8 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FYARRO Sales: FYARRO sales achieved a cumulative $24.4 million for the full year of 2023, representing a 60% growth over the prior year.
nab-sirolimus Trials: Enrollment is underway for Phase II trials evaluating nab-sirolimus in neuroendocrine tumors and advanced endometrial cancer.
Market Potential for nab-sirolimus: Approximately 16,000 new patients with TSC1 or TSC2 mutations are identified annually in the U.S., representing a multibillion-dollar addressable market.
Operational Streamlining: In early 2024, measures were implemented to streamline operations and reduce costs, including headcount reductions.
Clinical Development Focus: Aadi is focused on becoming a multi-indication precision oncology company, leveraging nab-sirolimus for various mTOR-driven cancers.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Sales Growth Risk: FYARRO sales growth of 60% over the prior year may face challenges due to competitive pressures in the oncology market.
Clinical Trial Risks: The interim results from the PRECISION 1 trial showed variability in response rates, particularly in the TSC2 arm, which may complicate interpretation and future development.
Regulatory Risks: The company faces regulatory risks associated with the approval processes for new therapies, which could impact timelines and market entry.
Financial Stability Risk: Despite a solid cash position of $108.8 million, the company has incurred a net loss of $65.8 million for the year, raising concerns about long-term financial sustainability.
Operational Risks: Recent headcount reductions and cost-cutting measures may impact operational efficiency and the ability to execute on clinical and commercial strategies.
Market Demand Risk: The potential market for nab-sirolimus is significant, but actual demand may vary based on treatment outcomes and competitive landscape.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FYARRO Sales: Achieved cumulative $24.4 million for the full year of 2023, representing a 60% growth over prior year.
PRECISION 1 Trial: Designed to evaluate nab-sirolimus for solid tumors with TSC1 or TSC2 mutations, with interim readout expected in Q3 2024.
Clinical Trials: Enrollment underway for Phase II trials targeting neuroendocrine tumors and advanced endometrial cancer.
Cash Runway: Cash runway extended into Q4 2025 following operational streamlining.
Net Product Sales Guidance: FYARRO net product sales were $6.3 million for Q4 2023, representing 6% growth over Q3 2023.
R&D Expenses: R&D expenses for the year amounted to $48.9 million, up from $32.7 million in the prior year.
Net Loss: Net loss for the year was $65.8 million, compared to $60.5 million in the prior year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
FYARRO net product sales Q4 2023: $6.3 million, representing 6% growth over Q3 2023 and 21% over the prior year quarter.
FYARRO full year sales 2023: $24.4 million, an increase of 60% over prior year sales of $15.2 million.
Cash position: $108.8 million in cash, cash equivalents, and short-term investments at the end of 2023.
Net loss Q4 2023: $16.3 million compared to $13.9 million in Q4 2022.
Net loss full year 2023: $65.8 million compared to $60.5 million in the prior year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What updates do you have around the remainder of the trials and any changes in enrollment dynamics since the interim data disclosure?
A:We anticipate continuing to enroll later line patients within the trial. We will report out the total 80 patients at the two-thirds interim later this year.
Q:When could you report initial data from the endometrial or NET studies? Any updates on the adagrasib combo trial?
A:We anticipate potentially sharing data on endometrial or neuroendocrine trial later this year. Both studies are actively enrolling patients.
Q:Can you provide details, guidance or commercial plans for FYARRO?
A:We are not going to provide guidance for this year. Sales have stabilized around the $6 million mark, and we expect incremental growth from here.
Q:What are the most important considerations for FDA to consider label as a tumor agnostic?
A:The FDA wants to see a variety of different tumor types represented in tumor agnostic studies, along with a reasonable response rate and good safety profile.
Q:Could you give us a sense of the sites open, how many sites are open and inclusion and exclusion criteria for the patients?
A:We probably wouldn't discuss a number of sites or number of patients at this point just given where we are in the trial.
Q:What other mutational backgrounds are sensitive to mTOR inhibitors?
A:There are many mutations along the mTOR pathway that may provide targets, but none have been specifically identified as a target for mTOR inhibition.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of sites open and the number of patients in the endometrial trial, stating they wouldn't discuss it at this point. Additionally, the response regarding other mutational backgrounds sensitive to mTOR inhibitors was vague, indicating many possibilities without specific evidence.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aadi Bioscience
Dr Lennon
FDA tumor
FYARRO outlook
II study
Instructions line
NET
NETs
PRECISION enrollment
PRECISION patient
PRECISION trial
Patients
Phase II
change
cutoff
design
detail
expectation
follow PRECISION
indication trial
label
letrozole
mTOR tumor
nab sirolimus
outlook FYARRO
patient trial
population
quarter sale
question follow
range
safety profile
setting
sirolimus type
site
third interim
trial line
trial update
tumor indication
tumor study
type tumor
variety tumor
AADI Transcript
Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript
Unknown8-10
The earnings call presents a mixed picture: stable financial performance with a decrease in net loss and increased FYARRO sales, but ongoing financial challenges and risks from clinical trials. The Q&A section highlights management's uncertainty in key areas, like TSC1 and 2 expectations, and vague responses on sales potential, which may concern investors. Despite positive cash flow and a promising market opportunity, uncertainties in trial outcomes and market adoption, along with lack of guidance, suggest a neutral short-term stock price movement.
Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture. Financial performance shows positive revenue growth and a strong cash position, but there are concerns about increased R&D expenses and net losses. The Q&A highlights ongoing trials with some promising interim results, but uncertainties remain about future trial outcomes and competitive pressures. Management's reluctance to provide specific guidance on FYARRO sales adds to the uncertainty. Overall, these factors suggest a neutral stock price movement in the short term.
Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call Transcript
Unknown11-8
The earnings call highlights several concerns: increasing net loss, high R&D and SG&A expenses, and heavy reliance on a single product (FYARRO). While FYARRO sales grew, they remain modest, and commercialization challenges persist. The PRECISION 1 trial carries significant risks, and management was vague in the Q&A, avoiding specifics on key trial details. Despite having cash reserves, the financial and clinical uncertainties overshadow positive aspects, leading to a negative sentiment.
Aadi Bioscience, Inc. (AADI) Q2 2023 Earnings Call Transcript
Neutral8-9
AADI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
